Leading Independent Advisory Firm Institutional Shareholder Services, Inc. Recommends Baudax Bio Shareholders Vote “For” the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders
June 30, 2021 07:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today...
Baudax Bio Announces Special Meeting of Shareholders to Vote on Proposed Increase in Number of Authorized Shares of Common Stock
June 18, 2021 16:05 ET
|
Baudax Bio, Inc.
MALVERN, Pa., June 18, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today...
Baudax Bio to Participate in the JMP Securities Life Sciences Conference
June 10, 2021 07:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today...
Baudax Bio’s ANJESO® Achieves Formulary Listing at Over 100 Institutions in Less Than One Year on the Market
June 08, 2021 07:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today...
Baudax Bio Announces $11.9 Million Registered Direct Offering
May 31, 2021 22:56 ET
|
Baudax Bio, Inc.
MALVERN, Pa., May 31, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today...
Baudax Bio Announces the Cancellation of Adjourned Portion of Annual Shareholder Meeting
May 28, 2021 16:05 ET
|
Baudax Bio, Inc.
MALVERN, Pa., May 28, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on developing and commercializing innovative products for acute care...
Baudax Bio to Present at the 2021 Jefferies Virtual Healthcare Conference
May 27, 2021 07:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., May 27, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today...
Baudax Bio Announces Publication of Phase IIIb ANJESO® Data in the Journal Pain Management
May 17, 2021 07:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the results of the Phase...
Leading Independent Advisory Firm Institutional Shareholder Services, Inc. Recommends Baudax Bio Shareholders Vote "For" the Proposed Additional Authorized Shares
May 13, 2021 07:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on developing and commercializing innovative products for acute care...
Leading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends Baudax Bio Shareholders Vote "For" The Additional Authorized Shares
May 12, 2021 09:02 ET
|
Baudax Bio, Inc.
MALVERN, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on developing and commercializing innovative products for acute care...